Scholars@Duke

• Background
• 

  Education, Training, & Certifications

  • Fellow, Internal Medicine, University Hospitals of Cleveland 1987 - 1990
  • Resident, Internal Medicine, University Hospitals of Cleveland 1985 - 1987
  • Intern, Internal Medicine, University Hospitals of Cleveland 1984 - 1985
  • M.D., Duke University 1984
• 

  Duke Appointment History

  • Consulting Associate in the Department of Medicine, Medicine, Medical Oncology, Medicine 1998 - 2008
  • Instructor, Temporary in the Department of Medicine, Medicine, Medical Oncology, Medicine 1998
• Publications & Artistic Works
• 

  Selected Publications

  • Academic Articles

    • Gasparetto, Cristina, Jon P. Gockerman, Louis F. Diehl, Carlos M. de Castro, Joseph O. Moore, Gwynn D. Long, Mitchell E. Horwitz, et al. “"Short course" bortezomib plus melphalan and prednisone as induction prior to transplant or as frontline therapy for nontransplant candidates in patients with previously untreated multiple myeloma..” Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation 16, no. 1 (January 2010): 70–77. https://doi.org/10.1016/j.bbmt.2009.08.017.
       Full Text
    • Sedwick, W. D., R. D. Anderson, J. Baxter, S. Donover, S. Schneiter, and M. L. Veigl. “Correlation of doxorubicin footprints with deletion endpoints in lacO of E. coli..” Mutation Research 326, no. 1 (January 1995): 17–27. https://doi.org/10.1016/0027-5107(94)00155-x.
       Full Text
    • Veigl, M. L., S. P. Donover, R. D. Anderson, L. Akst, C. E. Sedwick, and W. D. Sedwick. “Effect of isopropyl-beta-D-thiogalactopyranosid induction of the lac operon on the specificity of spontaneous and doxorubicin-induced mutations in Escherichia coli..” Environmental and Molecular Mutagenesis 26, no. 1 (January 1995): 16–25. https://doi.org/10.1002/em.2850260104.
       Full Text
    • Anderson, R. D., and N. A. Berger. “International Commission for Protection Against Environmental Mutagens and Carcinogens. Mutagenicity and carcinogenicity of topoisomerase-interactive agents..” Mutation Research 309, no. 1 (August 1994): 109–42. https://doi.org/10.1016/0027-5107(94)90048-5.
       Full Text
    • Anderson, R. D., M. L. Veigl, J. Baxter, and W. D. Sedwick. “Excision repair reduces doxorubicin-induced genotoxicity..” Mutation Research 294, no. 3 (October 1993): 215–22. https://doi.org/10.1016/0921-8777(93)90004-z.
       Full Text
    • Anderson, R. D., C. Y. Bao, D. T. Minnick, J. Baxter, M. L. Veigl, and W. D. Sedwick. “Sequencing of double-stranded polymerase chain reaction products for mutation analysis..” Mutation Research 288, no. 1 (July 1993): 181–85. https://doi.org/10.1016/0027-5107(93)90219-6.
       Full Text
    • Anderson, R. D., M. L. Veigl, J. Baxter, and W. D. Sedwick. “DNA sequence specificity of doxorubicin-induced mutational damage in uvrB- Escherichia coli..” Cancer Research 51, no. 15 (August 1991): 3930–37.
    • Anderson, R. D., M. L. Veigl, and W. D. Sedwick. “Rapid mapping of deletion and duplication mutations by the polymerase chain reaction..” Biochem Biophys Res Commun 170, no. 2 (July 31, 1990): 416–20.
       Link to Item

Some information on this profile has been compiled automatically from Duke databases and external sources. (Our About page explains how this works.) If you see a problem with the information, please write to Scholars@Duke and let us know. We will reply promptly.